Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a distinguished leader with extensive clinical development and leadership experience and who has served on the Tango Board of Directors since 2018, who will drive the next phase of company growth.

GlobeNewsWire • Jan 8, 2026

Tango Therapeutics Appoints Sung Lee to Board of Directors

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of experience in finance leadership in the biopharmaceutical and technology industries.

GlobeNewsWire • Jan 5, 2026

3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026

EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.

Zacks Investment Research • Dec 22, 2025

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST/12:45pm EST.

GlobeNewsWire • Dec 17, 2025

5 Biotech Stocks to Watch for Potential Upside

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.

Zacks Investment Research • Dec 17, 2025

Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 37.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Dec 8, 2025

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 1:30pm ET.

GlobeNewsWire • Nov 26, 2025

Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High?

The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 46.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Nov 21, 2025

Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy

Tango Therapeutics, Inc. is initiated with a Buy rating due to strong progress with its lead PRMT5 inhibitor, vopimetostat, for MTAP-deleted cancers. TNGX reported positive phase 1/2 results in 2nd-line MTAP-deleted pancreatic cancer, doubling median progression-free survival and objective response rate versus historical controls. A pivotal trial for vopimetostat in 2nd-line MTAP-deleted pancreatic cancer patients is set for 2026, with additional combination and expansion studies planned for broader indications.

Seeking Alpha • Nov 21, 2025